Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATIR101 vs PTCy in Haploidentical HSCT for Hematologic Malignancies
NCT02999854Phase 3Terminated
- Sponsor
- Kiadis Pharma
- Start
- Nov 2017
- Primary completion
- Nov 2021
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of ATIR101 in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Kiadis Pharma. Primary endpoint: Graft-versus-host Disease-free, Relapse-free Survival at 24 months. Started Nov 2017; status: terminated.
02
Drugs
ATIR101
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02999854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02999854.